Skip to main content
. 2019 Feb 26;3(4):670–680. doi: 10.1182/bloodadvances.2018027003

Figure 1.

Figure 1.

NRM and relapse, DFS, and OS in 3 cohorts. Relapse and NRM for adults (CR1/CR2) (A), pediatric patients (CR1/CR2, MAC) (C), and all patients with active disease (MAC) (E). DFS and OS for adults (CR1/CR2) (B), pediatric patients (CR1/CR2, MAC) (D), and all patients with active disease (MAC) (F).